The Development of New, Non-steroidal Anti-Asthma Drugs with Novel Modes of Action

点击翻译按钮获取中文摘要

Asthma represents one of Australia's most significant chronic disease states. It adversely affects the lives of many hundreds of thousands of citizens and represents a growing problem, especially amongst younger members of the population. The start-up biotech company Cryptopharma has recently identified a family of steroid derivatives that deliver, through a novel mode of action, significant anti-asthma activity in in-vivo models. The purpose of the present work is to develop, through comprehensive synthetic organic chemistry and medicinal chemistry-type studies, non-steroidal analogues of Cryptopharma's lead compound that can be used clinically in the treatment of asthma.